The Institute generates news every day. Some findings are groundbreaking—some represent smaller steps. But ultimately, it is the combination of both that makes scientific advancement possible. Here is a little selection of the latest stories making it out to the wider world.
LIT scientists Prof. Hinrich Abken, Prof. Markus Feuerer, Prof. Luca Gattinoni and Prof. Michael Rehli are featured in the prestigious Stanford ranking of the world’s top 2% of scientists.
The LIT Retreat took place on September 16 and 17, 2024 at Schloss Hirschberg.
Gabriele Inchingolo was honored as one of the Best Abstract Awardees at the 3rd Translational Research Conference “IMMUNE & CELLULAR THERAPIES: Focus on Advanced Gene-Engineered Immune Cells” September 13-15, 2024 in Malahide (Dublin), Ireland.
An international team of researchers, led by Professor Luca Gattinoni at the Leibniz Institute for Immunotherapy (LIT), has developed an innovative mitochondrial transfer platform to supercharge CD8+ T cells, enabling them to overcome exhaustion and more effectively fight tumor cells.
Prof. Philipp Beckhove, Scientific Director of the LIT, was guest in the podcast “Tonspur Wissen” by Leibniz Association and Rheinische Post. He talked with journalist Ursula Weidenfeld about new developments in fighting cancer with immunotherapy (in German).
Researchers at the Leibniz Institute for Immunotherapy (LIT) studied hundreds of patients with acute myeloid leukemia (AML). They discovered that specific mutations in the STAG2 protein cause altered DNA folding in the cell nucleus, thereby contributing to the development of AML.
Researchers at the Leibniz Institute for Immunotherapy (LIT), University Hospital Regensburg (UKR) and the National Heart, Lung, and Blood Institute (NHLBI) have engineered CD8+ T cells to artificially express the gene LMO4, thereby enhancing their effectiveness against tumors.
Researchers at the Leibniz Institute for Immunotherapy (LIT) describe a new type of regulation of immune cells by so-called ‘jumping genes.’
Due to exemplary actions in the field of equal opportunity-oriented personnel and organizational policies, Leibniz Institute for Immunotherapy is awarded the TOTAL E-QUALITY award for the second time, which is valid for the years 2024 to 2026.
More than 150 leading scientists from around the world discussed latest developments in immunological research and the treatment of diseases such as cancer, autoimmune diseases, and chronic inflammation at the International Symposium of the Leibniz Institute for Immunotherapy June 26th – 27th, 2024 in Regensburg.
